Skip to main content
Premium Trial:

Request an Annual Quote

SensiGen to Use Sequenom Tools to Develop Assays That the Firms Will Co-Market

NEW YORK (GenomeWeb News) — SensiGen today said it will use Sequenom’s MassArray platform and QGE gene-expression tools to continue to develop several disease assays that the companies will co-market to reference labs for an indefinite period.
 
The first of SensiGen’s AttoSense tests to be developed on the Sequenom platform will be an assay for human papillomavirus. The company plans to submit that test to the US Food and Drug Administration by 2009.
 
SensiGen plans to develop three other tests, including assays for chronic kidney disease, inflammatory bowel disease, and lupus.
 
The companies said the AttoSense assay method can detect DNA from viruses, bacteria, blood, urine, and tissue.
 
Financial terms of the agreement were not released.

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.